Most people understand that cancer isn’t a generic, one-size-fits-all diagnosis. But prostate cancer diagnosis remains controversial because in many cases alternative prostate cancer treatment — or no treatment at all — is the appropriate path.
In fact, Dr. Herbert Lapor, the chairman of the department of urology at New York University Langone Medical Center, recently told CBS News that a majority of diagnosed prostate cancer “is not significant.”
That’s because prostate cancer isn’t always aggressive and often doesn’t pose a health risk. While 16% of men are diagnosed with prostate cancer, only 3% percent die from the disease. For patients, traditional cancer treatment, including radiation therapy or removing the prostate, is not only unnecessary but may be worse than the disease itself.
Prostate cancer is almost always detected through screening with the prostate-specific antigen (PSA) test. Elevated levels indicate the presence of cancer. If a biopsy of the prostate confirms it’s cancerous, a pathologist assesses how different the cancer tissue looks compared with normal prostate tissue and assigns what’s called a Gleason scale score ranging from 2 to 10.
At EuroMed Foundation, our medical staff uses the Gleason scale score to assess the risk posed by the cancer to help determine whether treatment is necessary and, if so, the appropriate holistic treatment for prostate cancer or combination of complementary therapies. In some cases, we recommend postponing therapy while actively monitoring PSA levels.